Post Profile






Novartis’ Gilenya Improves Cognition, Reduces Relapses and MS Lesions, Phase 4 Trial Shows

Novartis‘ Gilenya and interferon beta-1b-based therapies stop multiple sclerosis patients’ cognitive decline, a Phase 4 clinical trial shows. Gilenya (fingolimod) also reduces patients’ relapses and the number of their brain lesions — areas where a protein coating that protects nerve cells has deteriorated, researchers found. The study, published in the Journal of Neurology, is titled “Efficacy of fingolimod […] The post Novartis’ Gilenya Improves Cognition, Reduces Relapses and MS Lesions, Phase 4 Trial Shows appeared first on Multiple Sclerosis News Today.
read more

share

Related Posts


New data show Gilenya® (fingolimod) reduced brain volume loss by one third and confirm link between brain volume loss and MS disability

Health : Medical News Today

Novartis has announced new data indicating that continued treatment with Gilenya® (fingolimod) led to a reduction in brain volume loss in people with relapsing remitting multiple sclerosis (RRMS), and was associated with a higher pr...

Apitope’s ATX-MS-1468 Therapy Decreases Brain Lesions in Relapsing MS Patients

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

Treatment with Apitope’s lead agent, ATX-MS-1467, decreased brain lesions in patients with relapsing multiple sclerosis (MS) in a now-completed Phase 2a clinical trial. ATX-MS-1467 is a potential disease-modifying agent with an immu...

Long-term Treatment with Gilenya Found to Limit Lesions, Relapses in Japanese MS Patients

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

Continuous treatment with Gilenya (fingolimod) helps limit relapses and detectable lesions in multiple sclerosis (MS) patients, according to a three-year, follow-up study in Japan. The results confirm the findings of trials conducte...

Japanese Study Finds Gilenya Limits Lesions and Relapses in MS Patients

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

A Japanese study has found that long-term use of the drug Gilenya (fingolimod) helps to limit brain lesions and relapses in multiple sclerosis patients. Gilenya could help treat SPMS by countering astrocytes. Find out more here.  Th...

Real-world Spanish Study Confirms Gilenya’s Ability to Reduce Multiple Sclerosis Relapses

Diseases & Conditions / Multiple Sclerosis : Multiple Sclerosis News Today

A real-world medical-facilities setting has confirmed clinical trial findings that Gilenya (fingolimod) can reduce multiple sclerosis relapses, according to a Spanish study published in Plos One. Gilenya, developed by Novartis Pharm...

Comments


Copyright © 2016 Regator, LLC